Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Luen SJ, et al. Among authors: andreopoulou e. Ann Oncol. 2019 Feb 1;30(2):236-242. doi: 10.1093/annonc/mdy547. Ann Oncol. 2019. PMID: 30590484 Free article.
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Fasano GA, Bayard S, Chen Y, Varella L, Cigler T, Bensenhaver J, Simmons R, Swistel A, Marti J, Moore A, Andreopoulou E, Ng J, Brandmaier A, Formenti S, Ali H, Davis M, Newman L. Fasano GA, et al. Among authors: andreopoulou e. Breast Cancer Res Treat. 2022 Feb;192(1):163-173. doi: 10.1007/s10549-021-06481-4. Epub 2022 Jan 13. Breast Cancer Res Treat. 2022. PMID: 35022867
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL. Kalinsky K, et al. Among authors: andreopoulou e. Clin Transl Oncol. 2018 Nov;20(11):1474-1483. doi: 10.1007/s12094-018-1888-2. Epub 2018 May 7. Clin Transl Oncol. 2018. PMID: 29736694 Free PMC article. Clinical Trial.
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E, Elemento O, Chang J, Inghirami G, Gao D, Ryu S, Mittal V. Yomtoubian S, et al. Among authors: andreopoulou e. Cell Rep. 2020 Jan 21;30(3):755-770.e6. doi: 10.1016/j.celrep.2019.12.056. Cell Rep. 2020. PMID: 31968251 Free article.
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
Tolaney SM, Kalinsky K, Kaklamani VG, D'Adamo DR, Aktan G, Tsai ML, O'Regan RM, Kaufman PA, Wilks ST, Andreopoulou E, Patt DA, Yuan Y, Wang G, Savulsky C, Xing D, Kleynerman E, Karantza V, Diab S. Tolaney SM, et al. Among authors: andreopoulou e. Clin Cancer Res. 2021 Jun 1;27(11):3061-3068. doi: 10.1158/1078-0432.CCR-20-4726. Epub 2021 Mar 16. Clin Cancer Res. 2021. PMID: 33727258 Clinical Trial.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Kearney M, Franks L, Lee S, Tiersten A, Makower DF, Cigler T, Mundi P, Chi DC, Goel A, Klein P, Andreopoulou E, Sparano J, Trivedi M, Accordino M, Califano A, Hershman DL, Silva J, Kalinsky K. Kearney M, et al. Among authors: andreopoulou e. Breast Cancer Res Treat. 2021 Aug;189(1):177-185. doi: 10.1007/s10549-021-06306-4. Epub 2021 Jun 24. Breast Cancer Res Treat. 2021. PMID: 34169393 Free PMC article. Clinical Trial.
73 results